Time to stop settling for less?

Professor Dan Iosifescu

Day-one of ECNP 2015 and balmy weather in Amsterdam did not distract a large number of eager delegates from attending and adding their voice to one of the opening satellite sessions of the congress. Our correspondent provides a flavour of the issues, challenges and treatment strategies aired during a session focusing on MDD management.

By 2030, it is predicted that major depressive disorder (MDD) will overtake cardiovascular disease to become the leading cause of lost DALYs (disability-Adjusted Life Years) linked with ill-health or disease, a burden which reflects the fact that as many as 1 in 2 patients do not respond adequately to antidepressant therapy.

This was one of the stark messages at a satellite symposium entitled “Optimising treatment strategies for patients with MDD who do not respond adequately to antidepressants”, chaired by Professor Michael Thase of the Perelman School of Medicine if the University of Pennsylvannia, USA.

 

Ripple effects

Patients with MDD are impaired across multiple domains, said Professor Dan Iosifescu of the Icahn School of Medicine at Mount Sinai, New York, USA. He reminded delegates that in addition to the symptom burden posed by MDD, patients often experience cognitive deficits and impairments in social functioning and relationships that have far-reaching ripple effects.

Social relationships, work prospects, marriages and personal relationships, and the family and support systems of a patient with MDD, can all be affected by the condition. Professor Iosifescu highlighted that this burden in part reflects the fact that large numbers of people with MDD do not achieve an adequate clinical response or remission despite ample availability of different classes of antidepressants.

 

Ever-decreasing circles

Professor Iosifescu went on to cite evidence that shows that for many patients with MDD, a pattern of inadequate response to treatment is then set in motion. He said data from the STAR*D study reveal that as many as 50% of people do not achieve a response to a first-line antidepressant therapy, and response rates become progressively lower with each additional line of treatment, with worsening outcomes for patients.

The vexed question is how best to address inadequate responses to antidepressant therapy.

Professor Iosifescu pointed out that strategies may include increasing the dose of antidepressant, switching treatments or augmenting antidepressant therapy with agents offering complementary pharmacological effects. This latter approach has the potential of retaining and building upon any benefits of initial therapy. He said that in a nutshell, patients with MDD want a full recovery, which according to Professor Iosifescu means good symptom control and functional recovery.

 

Far-reaching frustrations

This was view echoed by Professor Philip Gorwood of the Sainte-Anne Hospital, Paris, France, who was keen to remind delegates that many of the two-thirds of patients with MDD who fail to achieve full remission are frustrated by what current treatment strategies deliver. He stressed that quality of life is a key goal for patients and he said treatments need to offer the right balance between efficacy and safety.

Professor Gorwood highlighted that one of the signs that patients are seeking better responses to treatment is their willingness to try complementary and alternative medicines (CAMs).

Physicians are also keen to explore ways to support and help MDD patients achieve better response and remission rates. Professor Gorwood flagged a number of unmet needs – including the need for a wider choice of therapies, the need to understand which patients will best benefit from which treatment strategies and the importance of tolerable therapies which patients can comply with. Despite the fact that some of the recent research into the genetics of depression has been disappointing, Professor Gorwood remains hopefully and optimistic that the concept of personalized medicine – fitting the right treatments to the right patients – is a worthwhile and achievable future goal.

He and his presenter-colleagues also shared glimpses into the emerging and increasing evidence-base demonstrating that adjunctive use of atypical antipsychotics may offer a better-tailored strategy for addressing the burden of MDD that does not respond adequately to antidepressant therapy. Interestingly, he reported the results of a survey that showed that the main reasons not to prescribe an antipsychotic were a “wait and see” attitude among physicians and a focus on specific symptoms and tolerability concerns, suggesting that effective adjunctive treatments with an improved tolerability profile would be welcomed into the MDD armamentarium.

Our correspondent’s highlights from the symposium are meant as a fair representation of the scientific content presented. The views and opinions expressed on this page do not necessarily reflect those of Otsuka and Lundbeck.

Country selection
We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil
You are leaving Progress in Mind
Hello
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Congress
Register for access to Progress in Mind in your country